The storied Australian drug developer turning his skills to funds management
Professor Andrew Wilks has founded a new biotech fund targeting local early-stage medical research The fund, Synthesis Bioventures, aims to raise $75 million and so far has invested $15 million Wilks co-developed the FDA-approved myelofibrosis drug, …